BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ, Chan HL. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PLoS One. 2013;8:e62885. [PMID: 23638162 DOI: 10.1371/journal.pone.0062885] [Cited by in Crossref: 166] [Cited by in F6Publishing: 162] [Article Influence: 18.4] [Reference Citation Analysis]
Number Citing Articles
1 Malnick S, Maor Y. The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. Visc Med 2020;36:198-205. [PMID: 32775350 DOI: 10.1159/000507233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhang Q, Tian F, Zhao J, Zhang H, Zhai Q, Chen W. The influence of dietary patterns on gut microbiome and its consequences for nonalcoholic fatty liver disease. Trends in Food Science & Technology 2020;96:135-44. [DOI: 10.1016/j.tifs.2019.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Hullar MAJ, Jenkins IC, Randolph TW, Curtis KR, Monroe KR, Ernst T, Shepherd JA, Stram DO, Cheng I, Kristal BS, Wilkens LR, Franke A, Le Marchand L, Lim U, Lampe JW. Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. Gut Microbes 2021;13:1965463. [PMID: 34491886 DOI: 10.1080/19490976.2021.1965463] [Reference Citation Analysis]
4 Lau E, Carvalho D, Freitas P. Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed Res Int. 2015;2015:979515. [PMID: 26090468 DOI: 10.1155/2015/979515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
5 Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8:1466. [PMID: 29362454 DOI: 10.1038/s41598-018-19753-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 25.5] [Reference Citation Analysis]
6 Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-78. [DOI: 10.1038/s41575-018-0014-9] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 38.3] [Reference Citation Analysis]
7 Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. Lipids Health Dis 2021;20:22. [PMID: 33637088 DOI: 10.1186/s12944-021-01440-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Sobhonslidsuk A, Chanprasertyothin S, Pongrujikorn T, Kaewduang P, Promson K, Petraksa S, Ongphiphadhanakul B. The Association of Gut Microbiota with Nonalcoholic Steatohepatitis in Thais. Biomed Res Int 2018;2018:9340316. [PMID: 29682571 DOI: 10.1155/2018/9340316] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
9 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
10 Tsai MC, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients 2020;12:E820. [PMID: 32204538 DOI: 10.3390/nu12030820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
11 Lee DH, Kim MJ, Song EJ, Kim JH, Ahn J, Nam YD, Jang YJ, Ha TY, Jung CH. Nutrikinetic study of genistein metabolites in ovariectomized mice. PLoS One 2017;12:e0186320. [PMID: 29059247 DOI: 10.1371/journal.pone.0186320] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
12 Chiu CC, Ching YH, Li YP, Liu JY, Huang YT, Huang YW, Yang SS, Huang WC, Chuang HL. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients 2017;9:E1220. [PMID: 29113135 DOI: 10.3390/nu9111220] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
13 Panasevich MR, Meers GM, Linden MA, Booth FW, Perfield JW 2nd, Fritsche KL, Wankhade UD, Chintapalli SV, Shankar K, Ibdah JA, Rector RS. High-fat, high-fructose, high-cholesterol feeding causes severe NASH and cecal microbiota dysbiosis in juvenile Ossabaw swine. Am J Physiol Endocrinol Metab 2018;314:E78-92. [PMID: 28899857 DOI: 10.1152/ajpendo.00015.2017] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
14 Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Endotoxins and Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:770986. [PMID: 34777261 DOI: 10.3389/fendo.2021.770986] [Reference Citation Analysis]
15 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
16 Jin H, Xu X, Pang B, Yang R, Sun H, Jiang C, Shao D, Shi J. Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Benef Microbes 2021;:1-14. [PMID: 34511051 DOI: 10.3920/BM2020.0183] [Reference Citation Analysis]
17 Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol. 2019;5:1-10. [PMID: 30915401 DOI: 10.5114/ceh.2019.83151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
18 Li Q, Li M, Li F, Zhou W, Dang Y, Zhang L, Ji G. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. J Ethnopharmacol 2020;258:112896. [PMID: 32325178 DOI: 10.1016/j.jep.2020.112896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Duarte SMB, Stefano JT, Miele L, Ponziani FR, Souza-Basqueira M, Okada LSRR, de Barros Costa FG, Toda K, Mazo DFC, Sabino EC, Carrilho FJ, Gasbarrini A, Oliveira CP. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. Nutr Metab Cardiovasc Dis. 2018;28:369-384. [PMID: 29482963 DOI: 10.1016/j.numecd.2017.10.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
20 Delzenne NM, Knudsen C, Beaumont M, Rodriguez J, Neyrinck AM, Bindels LB. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut–liver axis. Proc Nutr Soc 2019;78:319-28. [DOI: 10.1017/s0029665118002756] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 11.7] [Reference Citation Analysis]
21 Costa MAC, Vilela DLS, Fraiz GM, Lopes IL, Coelho AIM, Castro LCV, Martin JGP. Effect of kombucha intake on the gut microbiota and obesity-related comorbidities: A systematic review. Crit Rev Food Sci Nutr 2021;:1-16. [PMID: 34698580 DOI: 10.1080/10408398.2021.1995321] [Reference Citation Analysis]
22 Doré J, Multon MC, Béhier JM, Affagard H, Andremont A, Barthélémy P, Batista R, Bonneville M, Bonny C, Boyaval G, Chamaillard M, Chevalier MP, Cordaillat-Simmons M, Cournarie F, Diaz I, Guillaume E, Guyard C, Jouvin-Marche E, Martin FP, Petiteau D; les participants à la table ronde 2 des Ateliers de Giens XXXII. Microbiote intestinal : qu’en attendre au plan physiologique et thérapeutique ? Therapie 2017;72:1-19. [PMID: 28214070 DOI: 10.1016/j.therap.2017.01.001] [Reference Citation Analysis]
23 Yamamoto K, Kushida M, Tsuduki T. The effect of dietary lipid on gut microbiota in a senescence-accelerated prone mouse model (SAMP8). Biogerontology 2018;19:367-83. [DOI: 10.1007/s10522-018-9764-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
24 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
25 Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-775. [PMID: 26600078 DOI: 10.1002/hep.28356 doi: 10.1002/hep.28356] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Khan AA, Nema V, Khan Z. Current status of probiotics for prevention and management of gastrointestinal cancers. Expert Opin Biol Ther 2021;21:413-22. [PMID: 33034210 DOI: 10.1080/14712598.2021.1828858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Grąt M, Hołówko W, Wronka KM, Grąt K, Lewandowski Z, Kosińska I, Krasnodębski M, Wasilewicz M, Gałęcka M, Szachta P, Zborowska H, Patkowski W, Krawczyk M. The relevance of intestinal dysbiosis in liver transplant candidates. Transpl Infect Dis 2015;17:174-84. [PMID: 25728703 DOI: 10.1111/tid.12352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
28 Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Lindén J, Tiirola M, Lahti L, Pekkala S. Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats. Nutrients 2020;12:E3225. [PMID: 33105554 DOI: 10.3390/nu12113225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ji Y, Yin Y, Sun L, Zhang W. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int J Mol Sci 2020;21:E3066. [PMID: 32357561 DOI: 10.3390/ijms21093066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
30 Zhang N, Gou Y, Liang S, Chen N, Liu Y, He Q, Zhang J. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. J Immunol Res 2021;2021:4973589. [PMID: 34722779 DOI: 10.1155/2021/4973589] [Reference Citation Analysis]
31 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 16.0] [Reference Citation Analysis]
32 Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 2019;17:296-306. [PMID: 30196156 DOI: 10.1016/j.cgh.2018.08.065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 15.5] [Reference Citation Analysis]
33 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
34 Ghoshal UC, Goel A, Quigley EMM. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. Indian J Gastroenterol 2020;39:9-21. [PMID: 32291578 DOI: 10.1007/s12664-020-01027-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
35 Lin D, Lacey EA, Bach BH, Bi K, Conroy CJ, Suvorov A, Bowie RCK. Gut microbial diversity across a contact zone for California voles: Implications for lineage divergence of hosts and mitonuclear mismatch in the assembly of the mammalian gut microbiome. Mol Ecol 2020;29:1873-89. [PMID: 32282951 DOI: 10.1111/mec.15443] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Demir M, Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Scholz CJ, Kretzschmar A, Roderburg C, Lammert F, Goeser T, Kasper P, Steffen HM. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time? J Gastroenterol Hepatol 2020;35:1969-77. [PMID: 32267559 DOI: 10.1111/jgh.15071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
37 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 33.7] [Reference Citation Analysis]
38 Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2021;41:87-102. [PMID: 33957682 DOI: 10.1055/s-0040-1719174] [Reference Citation Analysis]
39 Kang Y, Zhang X, Cai Y, Su J, Kong X. Gut microbiota and metabolic disease: from pathogenesis to new therapeutic strategies. Reviews in Medical Microbiology 2016;27:141-52. [DOI: 10.1097/mrm.0000000000000085] [Cited by in Crossref: 11] [Article Influence: 1.8] [Reference Citation Analysis]
40 Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
41 Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Doré J, Multon M, Béhier J, Affagard H, Andremont A, Barthélémy P, Batitsa R, Bonneville M, Bonny C, Boyaval G, Chamaillard M, Chevalier M, Cordaillat-simmons M, Cournarie F, Diaz I, Guillaume E, Guyard C, Jouvin-marche E, Martin F, Petiteau D. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect? Therapies 2017;72:21-38. [DOI: 10.1016/j.therap.2016.12.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
43 Albhaisi SAM, Bajaj JS. The Influence of the Microbiome on NAFLD and NASH. Clin Liver Dis (Hoboken) 2021;17:15-8. [PMID: 33552480 DOI: 10.1002/cld.1010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-75. [PMID: 26600078 DOI: 10.1002/hep.28356] [Cited by in Crossref: 512] [Cited by in F6Publishing: 488] [Article Influence: 85.3] [Reference Citation Analysis]
45 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34453142 DOI: 10.1038/s41575-021-00499-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019;1:214-26. [PMID: 32039372 DOI: 10.1016/j.jhepr.2019.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
48 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
49 Shi J, Yang Y, Xu W, Cai H, Wu J, Long J, Cai Q, Zheng W, Flynn CR, Shu XO, Yu D. Sex-Specific Associations between Gut Microbiome and Non-Alcoholic Fatty Liver Disease among Urban Chinese Adults. Microorganisms 2021;9:2118. [PMID: 34683439 DOI: 10.3390/microorganisms9102118] [Reference Citation Analysis]
50 Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, Torimura T, Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayashi N, Sumida Y, Saito S, Nakajima A. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:2275-84. [PMID: 33709477 DOI: 10.1111/jgh.15487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
51 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
53 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
54 Jadhav K, Cohen TS. Can You Trust Your Gut? Front Endocrinol (Lausanne). 2020;11:592157. [PMID: 33193105 DOI: 10.3389/fendo.2020.592157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
55 Catinean A, Neag MA, Muntean DM, Bocsan IC, Buzoianu AD. An overview on the interplay between nutraceuticals and gut microbiota. PeerJ 2018;6:e4465. [PMID: 29576949 DOI: 10.7717/peerj.4465] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
56 Stadlbauer V, Leber B, Lemesch S, Trajanoski S, Bashir M, Horvath A, Tawdrous M, Stojakovic T, Fauler G, Fickert P, Högenauer C, Klymiuk I, Stiegler P, Lamprecht M, Pieber TR, Tripolt NJ, Sourij H. Lactobacillus casei Shirota Supplementation Does Not Restore Gut Microbiota Composition and Gut Barrier in Metabolic Syndrome: A Randomized Pilot Study. PLoS One 2015;10:e0141399. [PMID: 26509793 DOI: 10.1371/journal.pone.0141399] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
57 McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open 2014;4:e005047. [PMID: 25157183 DOI: 10.1136/bmjopen-2014-005047] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 11.8] [Reference Citation Analysis]
58 Martínez-Montoro JI, Kuchay MS, Balaguer-Román A, Martínez-Sánchez MA, Frutos MD, Fernández-García JC, Ramos-Molina B. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. Obes Rev 2021;:e13367. [PMID: 34729904 DOI: 10.1111/obr.13367] [Reference Citation Analysis]
59 So SS, Wan ML, El-Nezami H. Probiotics-mediated suppression of cancer. Curr Opin Oncol 2017;29:62-72. [PMID: 27792053 DOI: 10.1097/CCO.0000000000000342] [Cited by in Crossref: 39] [Cited by in F6Publishing: 13] [Article Influence: 7.8] [Reference Citation Analysis]
60 Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2015;14:572-81. [PMID: 26663004 DOI: 10.1016/s1499-3872(15)60026-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
61 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
62 John OD, Mouatt P, Majzoub ME, Thomas T, Panchal SK, Brown L. Physiological and Metabolic Effects of Yellow Mangosteen (Garcinia dulcis) Rind in Rats with Diet-Induced Metabolic Syndrome. Int J Mol Sci 2019;21:E272. [PMID: 31906096 DOI: 10.3390/ijms21010272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
63 Hu Y, Le Leu RK, Christophersen CT, Somashekar R, Conlon MA, Meng XQ, Winter JM, Woodman RJ, McKinnon R, Young GP. Manipulation of the gut microbiota using resistant starch is associated with protection against colitis-associated colorectal cancer in rats. Carcinogenesis. 2016;37:366-375. [PMID: 26905582 DOI: 10.1093/carcin/bgw019] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 12.5] [Reference Citation Analysis]
64 Rubio C, Puerto M, García-Rodríquez JJ, Lu VB, García-Martínez I, Alén R, Sanmartín-Salinas P, Toledo-Lobo MV, Saiz J, Ruperez J, Barbas C, Menchén L, Gribble FM, Reimann F, Guijarro LG, Carrascosa JM, Valverde ÁM. Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice. Mol Metab 2020;35:100954. [PMID: 32244182 DOI: 10.1016/j.molmet.2020.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Li F, Sun G, Wang Z, Wu W, Guo H, Peng L, Wu L, Guo X, Yang Y. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci China Life Sci 2018;61:770-8. [PMID: 29948900 DOI: 10.1007/s11427-017-9303-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
66 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
67 Moszak M, Szulińska M, Walczak-Gałęzewska M, Bogdański P. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. Int J Environ Res Public Health 2021;18:1616. [PMID: 33567710 DOI: 10.3390/ijerph18041616] [Reference Citation Analysis]
68 Shin NR, Bose S, Wang JH, Ansari A, Lim SK, Chin YW, Choi HS, Kim H. Flos Lonicera Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation. Front Microbiol. 2017;8:2271. [PMID: 29204141 DOI: 10.3389/fmicb.2017.02271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
69 Knorr J, Wree A, Tacke F, Feldstein AE. The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Semin Liver Dis 2020;40:298-306. [PMID: 32526788 DOI: 10.1055/s-0040-1708540] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
70 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
71 Engstler AJ, Aumiller T, Degen C, Dürr M, Weiss E, Maier IB, Schattenberg JM, Jin CJ, Sellmann C, Bergheim I. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut. 2016;65:1564-1571. [PMID: 26006114 DOI: 10.1136/gutjnl-2014-308379] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
72 Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 2021. [PMID: 34664301 DOI: 10.1111/jgh.15713] [Reference Citation Analysis]
73 Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin Obes. 2014;4:243-253. [PMID: 25825857 DOI: 10.1111/cob.12068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
74 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 16.4] [Reference Citation Analysis]
75 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, Mckenzie C, Summers K, Reid G, Burton JP, Silverman M. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol 2020;115:1055-65. [DOI: 10.14309/ajg.0000000000000661] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
77 Notarnicola M, Osella AR, Caruso MG, Pesole PL, Lippolis A, Tutino V, Bonfiglio C, De Nunzio V, Scavo MP, Mirizzi A, Franco I, Lippolis T, D'Alessandro R, Refolo MG, Messa C. Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions. Int J Mol Sci 2021;22:3899. [PMID: 33918878 DOI: 10.3390/ijms22083899] [Reference Citation Analysis]
78 Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020;39:613-27. [PMID: 31828683 DOI: 10.1007/s10096-019-03746-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
79 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
80 Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 2015;15:169. [PMID: 26635079 DOI: 10.1186/s12876-015-0400-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
81 Zhao Y, Zhou J, Liu J, Wang Z, Chen M, Zhou S. Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease. Front Pediatr 2019;7:518. [PMID: 31921729 DOI: 10.3389/fped.2019.00518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
82 Shen B, Wang J, Guo Y, Gu T, Shen Z, Zhou C, Li B, Xu X, Li F, Zhang Q, Cai X, Dong H, Lu L. Dextran Sulfate Sodium Salt-Induced Colitis Aggravates Gut Microbiota Dysbiosis and Liver Injury in Mice With Non-alcoholic Steatohepatitis. Front Microbiol 2021;12:756299. [PMID: 34795650 DOI: 10.3389/fmicb.2021.756299] [Reference Citation Analysis]
83 Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr 2017;8:240-52. [PMID: 28298269 DOI: 10.3945/an.116.013151] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 14.0] [Reference Citation Analysis]
84 Dong TS, Jacobs JP. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? Exp Biol Med (Maywood) 2019;244:408-18. [PMID: 30871368 DOI: 10.1177/1535370219836739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
85 Bibbò S, Ianiro G, Dore MP, Simonelli C, Newton EE, Cammarota G. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. Mediators Inflamm 2018;2018:9321643. [PMID: 29563854 DOI: 10.1155/2018/9321643] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
86 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
87 Neef A, Sanz Y. Future for probiotic science in functional food and dietary supplement development. Curr Opin Clin Nutr Metab Care 2013;16:679-87. [PMID: 24071779 DOI: 10.1097/MCO.0b013e328365c258] [Cited by in Crossref: 49] [Cited by in F6Publishing: 17] [Article Influence: 6.1] [Reference Citation Analysis]
88 He X, Ji G, Jia W, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci. 2016;17:300. [PMID: 26999104 DOI: 10.3390/ijms17030300] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
89 Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12 [DOI: 10.5497/wjp.v9.i1.1] [Reference Citation Analysis]
90 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
91 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412-425. [PMID: 27273168 DOI: 10.1038/nrgastro.2016.85] [Cited by in Crossref: 362] [Cited by in F6Publishing: 339] [Article Influence: 60.3] [Reference Citation Analysis]
92 Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
93 Scotti E, Boué S, Sasso GL, Zanetti F, Belcastro V, Poussin C, Sierro N, Battey J, Gimalac A, Ivanov NV, Hoeng J. Exploring the microbiome in health and disease: Implications for toxicology. Toxicology Research and Application 2017;1:239784731774188. [DOI: 10.1177/2397847317741884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Ducray HAG, Globa L, Pustovyy O, Roberts MD, Rudisill M, Vodyanoy V, Sorokulova I. Prevention of excessive exercise-induced adverse effects in rats with Bacillus subtilis BSB3. J Appl Microbiol 2020;128:1163-78. [PMID: 31814258 DOI: 10.1111/jam.14544] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
95 Elshaghabee FMF, Ghadimi D, Habermann D, de Vrese M, Bockelmann W, Kaatsch HJ, Heller KJ, Schrezenmeir J. Effect of Oral Administration of Weissella confusa on Fecal and Plasma Ethanol Concentrations, Lipids and Glucose Metabolism in Wistar Rats Fed High Fructose and Fat Diet. Hepat Med 2020;12:93-106. [PMID: 32617026 DOI: 10.2147/HMER.S254195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
96 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
97 Ahmed BA, Ong FJ, Barra NG, Blondin DP, Gunn E, Oreskovich SM, Szamosi JC, Syed SA, Hutchings EK, Konyer NB, Singh NP, Yabut JM, Desjardins EM, Anhê FF, Foley KP, Holloway AC, Noseworthy MD, Haman F, Carpentier AC, Surette MG, Schertzer JD, Punthakee Z, Steinberg GR, Morrison KM. Lower brown adipose tissue activity is associated with non-alcoholic fatty liver disease but not changes in the gut microbiota. Cell Rep Med 2021;2:100397. [PMID: 34622234 DOI: 10.1016/j.xcrm.2021.100397] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Tsai HJ, Tsai YC, Hung WW, Hung WC, Chang CC, Dai CY. Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients. J Pers Med 2021;11:238. [PMID: 33807075 DOI: 10.3390/jpm11030238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Lim S, Oh TJ, Koh KK. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Int J Cardiol 2015;201:408-14. [PMID: 26310987 DOI: 10.1016/j.ijcard.2015.08.107] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
100 Wirbel J, Zych K, Essex M, Karcher N, Kartal E, Salazar G, Bork P, Sunagawa S, Zeller G. Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox. Genome Biol 2021;22:93. [PMID: 33785070 DOI: 10.1186/s13059-021-02306-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
101 Ni J, Huang R, Zhou H, Xu X, Li Y, Cao P, Zhong K, Ge M, Chen X, Hou B, Yu M, Peng B, Li Q, Zhang P, Gao Y. Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma. Front Microbiol 2019;10:1458. [PMID: 31293562 DOI: 10.3389/fmicb.2019.01458] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
102 Adams LA, Morrison M. The Microbiome in Obesity, Diabetes, and NAFLD: What is Your Gut Telling Us? Curr Hepatology Rep 2016;15:96-102. [DOI: 10.1007/s11901-016-0299-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Schröder T, Kucharczyk D, Bär F, Pagel R, Derer S, Jendrek ST, Sünderhauf A, Brethack AK, Hirose M, Möller S, Künstner A, Bischof J, Weyers I, Heeren J, Koczan D, Schmid SM, Divanovic S, Giles DA, Adamski J, Fellermann K, Lehnert H, Köhl J, Ibrahim S, Sina C. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. Mol Metab 2016;5:283-95. [PMID: 27069868 DOI: 10.1016/j.molmet.2016.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
104 Velázquez KT, Enos RT, Bader JE, Sougiannis AT, Carson MS, Chatzistamou I, Carson JA, Nagarkatti PS, Nagarkatti M, Murphy EA. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. World J Hepatol 2019; 11(8): 619-637 [PMID: 31528245 DOI: 10.4254/wjh.v11.i8.619] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
105 Guohong-liu, Qingxi-zhao, Hongyun-wei. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Annals of Hepatology 2019;18:796-803. [DOI: 10.1016/j.aohep.2019.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
106 Boursier J, Diehl AM. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clin Liver Dis 2016;20:263-75. [PMID: 27063268 DOI: 10.1016/j.cld.2015.10.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
107 Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5:782-794. [PMID: 27617201 DOI: 10.1016/j.molmet.2016.06.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 109] [Article Influence: 20.2] [Reference Citation Analysis]
108 Bikel S, Valdez-Lara A, Cornejo-Granados F, Rico K, Canizales-Quinteros S, Soberón X, Del Pozo-Yauner L, Ochoa-Leyva A. Combining metagenomics, metatranscriptomics and viromics to explore novel microbial interactions: towards a systems-level understanding of human microbiome. Comput Struct Biotechnol J 2015;13:390-401. [PMID: 26137199 DOI: 10.1016/j.csbj.2015.06.001] [Cited by in Crossref: 110] [Cited by in F6Publishing: 90] [Article Influence: 15.7] [Reference Citation Analysis]
109 Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem 2019;120:2713-20. [PMID: 30443932 DOI: 10.1002/jcb.27635] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
110 Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2019;2019:7659509. [PMID: 31341422 DOI: 10.1155/2019/7659509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
111 Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Sieow BF, Nurminen TJ, Ling H, Chang MW. Meta-Omics- and Metabolic Modeling-Assisted Deciphering of Human Microbiota Metabolism. Biotechnol J 2019;14:e1800445. [PMID: 31144773 DOI: 10.1002/biot.201800445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 2021;73:126-43. [PMID: 32794259 DOI: 10.1002/hep.31523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
114 Kriss M, Verna EC, Rosen HR, Lozupone CA. Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. Transplantation 2019;103:668-78. [PMID: 30507741 DOI: 10.1097/TP.0000000000002568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat Commun 2017;8:1784. [PMID: 29209090 DOI: 10.1038/s41467-017-01973-8] [Cited by in Crossref: 347] [Cited by in F6Publishing: 305] [Article Influence: 69.4] [Reference Citation Analysis]
116 Evans SJ, Bassis CM, Hein R, Assari S, Flowers SA, Kelly MB, Young VB, Ellingrod VE, McInnis MG. The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res 2017;87:23-9. [PMID: 27988330 DOI: 10.1016/j.jpsychires.2016.12.007] [Cited by in Crossref: 131] [Cited by in F6Publishing: 117] [Article Influence: 21.8] [Reference Citation Analysis]
117 Abdul-Hai A, Abdallah A, Malnick SD. Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. World J Hepatol 2015; 7(12): 1679-1684 [PMID: 26140087 DOI: 10.4254/wjh.v7.i12.1679] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
118 Pang J, Xu W, Zhang X, Wong GL, Chan AW, Chan H, Tse C, Shu SS, Choi PC, Chan HL, Yu J, Wong VW. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:175-82. [DOI: 10.1111/apt.14119] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
119 Sookoian S, Pirola CJ. Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. Hepatobiliary Surg Nutr 2021;10:337-49. [PMID: 34159161 DOI: 10.21037/hbsn-20-270] [Reference Citation Analysis]
120 Jung Y, Kim I, Mannaa M, Kim J, Wang S, Park I, Kim J, Seo YS. Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease. Food Sci Biotechnol 2019;28:261-7. [PMID: 30815318 DOI: 10.1007/s10068-018-0433-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
121 Bastian WP, Hasan I, Lesmana CRA, Rinaldi I, Gani RA. Gut Microbiota Profiles in Nonalcoholic Fatty Liver Disease and Its Possible Impact on Disease Progression Evaluated with Transient Elastography: Lesson Learnt from 60 Cases. Case Rep Gastroenterol 2019;13:125-33. [PMID: 31011312 DOI: 10.1159/000498946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
122 Motta BM, Grander C, Gögele M, Foco L, Vukovic V, Melotti R, Fuchsberger C, De Grandi A, Cantaloni C, Picard A, Mascalzoni D, Rossini A, Pattaro C, Tilg H, Pramstaller PP. Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. J Transl Med 2019;17:408. [PMID: 31801616 DOI: 10.1186/s12967-019-02130-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Escobar JS, Klotz B, Valdes BE, Agudelo GM. The gut microbiota of Colombians differs from that of Americans, Europeans and Asians. BMC Microbiol 2014;14:311. [PMID: 25495462 DOI: 10.1186/s12866-014-0311-6] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 13.8] [Reference Citation Analysis]
124 Matsumoto K, Ichimura M, Tsuneyama K, Moritoki Y, Tsunashima H, Omagari K, Hara M, Yasuda I, Miyakawa H, Kikuchi K. Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PLoS One 2017;12:e0175406. [PMID: 28632732 DOI: 10.1371/journal.pone.0175406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
125 Economopoulos KP, Ward NL, Phillips CD, Teshager A, Patel P, Mohamed MM, Hakimian S, Cox SB, Ahmed R, Moaven O, Kaliannan K, Alam SN, Haller JF, Goldstein AM, Bhan AK, Malo MS, Hodin RA. Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase. Diabetes Obes Metab 2016;18:519-27. [PMID: 26876427 DOI: 10.1111/dom.12645] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
126 Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, Demir M. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. Sci Rep 2020;10:9385. [PMID: 32523101 DOI: 10.1038/s41598-020-66241-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
127 Quigley EM, Monsour HP. The gut microbiota and the liver: implications for clinical practice. Expert Rev Gastroenterol Hepatol 2013;7:723-32. [PMID: 24134195 DOI: 10.1586/17474124.2013.848167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
128 Bashir M, Prietl B, Tauschmann M, Mautner SI, Kump PK, Treiber G, Wurm P, Gorkiewicz G, Högenauer C, Pieber TR. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract. Eur J Nutr 2016;55:1479-89. [PMID: 26130323 DOI: 10.1007/s00394-015-0966-2] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 15.9] [Reference Citation Analysis]
129 Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1268-1281. [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
130 Watahiki T, Okada K, Warabi E, Nagaoka T, Suzuki H, Ishige K, Yanagawa T, Takahashi S, Mizokami Y, Tokushige K, Ariizumi SI, Yamamoto M, Shoda J. Gender difference in development of steatohepatitis in p62/Sqstm1 and Nrf2 double-knockout mice. Exp Anim 2020;69:395-406. [PMID: 32493884 DOI: 10.1538/expanim.20-0028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health 2019;38:81-8. [PMID: 31384519 DOI: 10.12938/bmfh.18-032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
132 Bilic-Curcic I, Cigrovski Berkovic M, Virovic-Jukic L, Mrzljak A. Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals . World J Hepatol 2021; 13(1): 80-93 [PMID: 33584988 DOI: 10.4254/wjh.v13.i1.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Oulas A, Zachariou M, Chasapis CT, Tomazou M, Ijaz UZ, Schmartz GP, Spyrou GM, Vlamis-Gardikas A. Putative Antimicrobial Peptides Within Bacterial Proteomes Affect Bacterial Predominance: A Network Analysis Perspective. Front Microbiol 2021;12:752674. [PMID: 34867874 DOI: 10.3389/fmicb.2021.752674] [Reference Citation Analysis]
134 Fu ZD, Cui JY. Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep 2017;3:101-13. [PMID: 28983453 DOI: 10.1007/s40495-017-0087-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
135 Traussnigg S, Halilbasic E, Hofer H, Munda P, Stojakovic T, Fauler G, Kashofer K, Krssak M, Wolzt M, Trauner M. Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. Wien Klin Wochenschr 2021;133:441-51. [PMID: 32930860 DOI: 10.1007/s00508-020-01735-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(42): 15518-15531 [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
137 Frank DN, Bales ES, Monks J, Jackman MJ, MacLean PS, Ir D, Robertson CE, Orlicky DJ, McManaman JL. Perilipin-2 Modulates Lipid Absorption and Microbiome Responses in the Mouse Intestine. PLoS One. 2015;10:e0131944. [PMID: 26147095 DOI: 10.1371/journal.pone.0131944] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
138 Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
139 Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B, Nobili V, Lorenza P. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci. 2014;15:684-711. [PMID: 24402126 DOI: 10.3390/ijms15010684] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
140 Akiyama K, Warabi E, Okada K, Yanagawa T, Ishii T, Kose K, Tokushige K, Ishige K, Mizokami Y, Yamagata K, Onizawa K, Ariizumi SI, Yamamoto M, Shoda J. Deletion of both p62 and Nrf2 spontaneously results in the development of nonalcoholic steatohepatitis. Exp Anim 2018;67:201-18. [PMID: 29276215 DOI: 10.1538/expanim.17-0112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
141 Joice R, Yasuda K, Shafquat A, Morgan XC, Huttenhower C. Determining microbial products and identifying molecular targets in the human microbiome. Cell Metab 2014;20:731-41. [PMID: 25440055 DOI: 10.1016/j.cmet.2014.10.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
142 Gomez Rosso L, Lhomme M, Meroño T, Dellepiane A, Sorroche P, Hedjazi L, Zakiev E, Sukhorukov V, Orekhov A, Gasparri J, Chapman MJ, Brites F, Kontush A. Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c. Biochim Biophys Acta Mol Cell Biol Lipids 2017;1862:188-95. [PMID: 27815221 DOI: 10.1016/j.bbalip.2016.10.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
143 Kim HN, Joo EJ, Cheong HS, Kim Y, Kim HL, Shin H, Chang Y, Ryu S. Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases. J Clin Med 2019;8:E1089. [PMID: 31344854 DOI: 10.3390/jcm8081089] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
144 Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015;42:1051-1063. [PMID: 26304302 DOI: 10.1111/apt.13376] [Cited by in Crossref: 102] [Cited by in F6Publishing: 97] [Article Influence: 14.6] [Reference Citation Analysis]
145 Leung DH, Yimlamai D. The intestinal microbiome and paediatric liver disease. Lancet Gastroenterol Hepatol 2017;2:446-55. [PMID: 28497760 DOI: 10.1016/S2468-1253(16)30241-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
146 Even M, Davail S, Rey M, Tavernier A, Houssier M, Bernadet MD, Gontier K, Pascal G, Ricaud K. Probiotics Strains Modulate Gut Microbiota and Lipid Metabolism in Mule Ducks. Open Microbiol J 2018;12:71-93. [PMID: 29755604 DOI: 10.2174/1874285801812010071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
147 Capurso L. Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol 2019;53 Suppl 1:S1-S41. [PMID: 30741841 DOI: 10.1097/MCG.0000000000001170] [Cited by in Crossref: 50] [Cited by in F6Publishing: 29] [Article Influence: 25.0] [Reference Citation Analysis]
148 Ezzaidi N, Zhang X, Coker OO, Yu J. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. Cancer Lett 2019;459:186-91. [PMID: 31185249 DOI: 10.1016/j.canlet.2019.114425] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
149 Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(19): 2083-2094 [PMID: 29785077 DOI: 10.3748/wjg.v24.i19.2083] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 51] [Article Influence: 14.3] [Reference Citation Analysis]
150 Iino C, Endo T, Mikami K, Hasegawa T, Kimura M, Sawada N, Nakaji S, Fukuda S. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. Hepatol Int 2019;13:748-56. [DOI: 10.1007/s12072-019-09987-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
151 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
152 Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem. 2015;48:923-930. [PMID: 26151226 DOI: 10.1016/j.clinbiochem.2015.06.023] [Cited by in Crossref: 128] [Cited by in F6Publishing: 132] [Article Influence: 18.3] [Reference Citation Analysis]
153 Grigor'eva IN. Gallstone Disease, Obesity and the Firmicutes/Bacteroidetes Ratio as a Possible Biomarker of Gut Dysbiosis. J Pers Med 2020;11:13. [PMID: 33375615 DOI: 10.3390/jpm11010013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
154 Sakai H, Shirakami Y, Shimizu M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol 2016; 22(1): 394-406 [PMID: 26755885 DOI: 10.3748/wjg.v22.i1.394] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
155 Koh JC, Loo WM, Goh KL, Sugano K, Chan WK, Chiu WY, Choi MG, Gonlachanvit S, Lee WJ, Lee WJ. Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. J Gastroenterol Hepatol. 2016;31:1405-1413. [PMID: 27010240 DOI: 10.1111/jgh.13385] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
156 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
157 Vespasiani-Gentilucci U, Gallo P, Picardi A. The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Arch Med Sci 2018;14:701-6. [PMID: 29765460 DOI: 10.5114/aoms.2016.58831] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
158 Rodríguez-Carrio J, López P, Sánchez B, González S, Gueimonde M, Margolles A, de Los Reyes-Gavilán CG, Suárez A. Intestinal Dysbiosis Is Associated with Altered Short-Chain Fatty Acids and Serum-Free Fatty Acids in Systemic Lupus Erythematosus. Front Immunol 2017;8:23. [PMID: 28167944 DOI: 10.3389/fimmu.2017.00023] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
159 Jian C, Luukkonen P, Sädevirta S, Yki-Järvinen H, Salonen A. Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clin Nutr 2021;40:207-16. [PMID: 32536582 DOI: 10.1016/j.clnu.2020.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
160 Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 17.5] [Reference Citation Analysis]
161 Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol 2015; 21(22): 6817-6819 [PMID: 26078557 DOI: 10.3748/wjg.v21.i22.6817] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
162 Satapathy SK, Banerjee P, Pierre JF, Higgins D, Dutta S, Heda R, Khan SD, Mupparaju VK, Mas V, Nair S, Eason JD, Kleiner DE, Maluf DG. Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis. Transplant Direct 2020;6:e625. [PMID: 33204823 DOI: 10.1097/TXD.0000000000001033] [Reference Citation Analysis]
163 Campo L, Eiseler S, Apfel T, Pyrsopoulos N. Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. J Clin Transl Hepatol. 2019;7:56-60. [PMID: 30944821 DOI: 10.14218/jcth.2018.00008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
164 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI, Valdes AM. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes 2020;11:569-80. [PMID: 31696774 DOI: 10.1080/19490976.2019.1681861] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
166 Iruzubieta P, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. J Clin Med 2020;9:E1369. [PMID: 32392712 DOI: 10.3390/jcm9051369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
167 Zhu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res. 2015;77:245-251. [PMID: 25310763 DOI: 10.1038/pr.2014.157] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 9.1] [Reference Citation Analysis]
168 Liu CZ, Chen W, Wang MX, Wang Y, Chen LQ, Zhao F, Shi Y, Liu HJ, Dou XB, Liu C, Chen H. Dendrobium officinale Kimura et Migo and American ginseng mixture: A Chinese herbal formulation for gut microbiota modulation. Chin J Nat Med 2020;18:446-59. [PMID: 32503736 DOI: 10.1016/S1875-5364(20)30052-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
169 Lim S, Taskinen MR, Borén J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes Rev 2019;20:599-611. [PMID: 30589487 DOI: 10.1111/obr.12820] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]